Incidence, Associated Factors, and Burden of Post COVID-19 Condition in Brazil
ConditionPost-Acute COVID-19 Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInova Medical
About this trial
This is a national retrospective cohort study with internet-based recruitment which intends to enroll 1,694 adult patients with COVID-19 diagnosis during the SARS-CoV-2 omicron wave in Brazil. Participants with confirmed symptomatic COVID-19 after january 2022 will be evaluated in order to assess incidence, potential risk factors and impact of post COVID-19 condition according to the WHO definition on health-related quality of life and other relevant patient-centered outcomes.
Eligibility criteria
Qualifiers
Age ≥ 18 years;
Brazilian resident;
Symptomatica COVID-19 confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) or antigen test for SARS-COV-2 after January 2022, with diagnosis at least 90 days before recruitment.
Disqualifiers
No availability to participate in remote research appointments;
Communication difficulty (aphasia, important hearing loss, non-portuguese speaker, severe dementia)
Refuse to provide informed consent
Trial design
Treatments tested in this trial
- Multiple exposures
Treatment groups
1,694 Participants
are divided into 1 treatment groupSponsors and collaborators
Inova Medical
Lead sponsor
Merck Sharp & Dohme LLC
Collaborator
Source ClinicalTrials.gov